SMO and skin basal cell carcinoma: The context‐dependent functions of primary cilia are also related to the resistance mechanism of SMO inhibitors.160, 161 Two SMO inhibitors, vismodegib and sonidegib, have been approved by the U.S. Food and Drug Administration for treatment in advanced or metastatic BCC.